Shanghai Covid-19 Lockdown challenges the global supply chain of medical devices

Since March 28, Chinese officials have imposed a lockdown on Shanghai’s more than 26 million residents, confining nearly all of them to their homes. This is the largest round of lockdown in Wuhan, China, since the COVID-19 outbreak in 2019.

Since March 28, Chinese officials have imposed a lockdown on Shanghai’s more than 26 million residents, confining nearly all of them to their homes. This is the largest round of lockdown in Wuhan, China, since the COVID-19 outbreak in 2019.

Enterprises in Shanghai and neighboring cities are currently limited to suspending production or semi-suspending production because even though medical device manufacturers like BQ Plus Medical have been allowed to resume production by the government, the surrounding roads are closed and production materials cannot be supplied in time. The community is closed and employees cannot return to work. This situation is expected to continue for some time and will inevitably lead to production shortages and delayed deliveries.

At this time, having a production base in different provinces becomes an advantage. In 2021, BQ Plus Medical acquired an infusion device production plant in northern Jiangsu, which passed TUV’s ISO13485 quality system audit, and has now become a major force in assembling finished products and delivering orders.